Sweden
· Delayed Price · Currency is SEK ODI Pharma AB Statistics
Total Valuation
ODI Pharma AB has a market cap or net worth of SEK 43.22 million. The enterprise value is 38.24 million.
| Market Cap | 43.22M |
| Enterprise Value | 38.24M |
Important Dates
The next estimated earnings date is Friday, February 21, 2025.
| Earnings Date | Feb 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ODI Pharma AB has 15.22 million shares outstanding. The number of shares has decreased by -0.76% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 15.22M |
| Shares Change (YoY) | -0.76% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 92.96% |
| Owned by Institutions (%) | n/a |
| Float | 1.07M |
Valuation Ratios
The trailing PE ratio is 130.86.
| PE Ratio | 130.86 |
| Forward PE | n/a |
| PS Ratio | 1.96 |
| PB Ratio | 82.01 |
| P/TBV Ratio | 82.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 115.75 |
| EV / Sales | 1.73 |
| EV / EBITDA | 34.46 |
| EV / EBIT | 34.55 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09
| Current Ratio | 1.09 |
| Quick Ratio | 1.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 1.45 |
Financial Efficiency
Return on equity (ROE) is 42.01% and return on invested capital (ROIC) is 87.97%.
| Return on Equity (ROE) | 42.01% |
| Return on Assets (ROA) | 10.75% |
| Return on Capital (ROIC) | 87.97% |
| Revenue Per Employee | 22.06M |
| Profits Per Employee | 330,320 |
| Employee Count | 1 |
| Asset Turnover | 3.43 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.35% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -45.35% |
| 50-Day Moving Average | 3.11 |
| 200-Day Moving Average | 5.25 |
| Relative Strength Index (RSI) | 44.04 |
| Average Volume (20 Days) | 5,880 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ODI Pharma AB had revenue of SEK 22.06 million and earned 330,320 in profits. Earnings per share was 0.02.
| Revenue | 22.06M |
| Gross Profit | 4.87M |
| Operating Income | 1.11M |
| Pretax Income | 518,921 |
| Net Income | 330,320 |
| EBITDA | 1.11M |
| EBIT | 1.11M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
| Cash & Cash Equivalents | 4.99M |
| Total Debt | n/a |
| Net Cash | 4.99M |
| Net Cash Per Share | 0.33 |
| Equity (Book Value) | 527,078 |
| Book Value Per Share | 0.03 |
| Working Capital | 521,103 |
Cash Flow
| Operating Cash Flow | -223,407 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 22.08%, with operating and profit margins of 5.02% and 1.50%.
| Gross Margin | 22.08% |
| Operating Margin | 5.02% |
| Pretax Margin | 2.35% |
| Profit Margin | 1.50% |
| EBITDA Margin | 5.03% |
| EBIT Margin | 5.02% |
| FCF Margin | n/a |
Dividends & Yields
ODI Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.76% |
| Shareholder Yield | 0.76% |
| Earnings Yield | 0.76% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |